A Real-world Study to Assess Safety and Effectiveness of Secukinumab in Pediatric Plaque Psoriasis Patients in China

Inclusion Criteria: Patients meeting all of the following criteria are eligible for inclusion in this study: * Written assent and informed consent must be obtained as per local regulations prior to any study procedures. * Diagnosed with moderate to severe plaque psoriasis. * Initiating treatment with Cosentyx® or having started Cosentyx® treatment within the last 4 weeks in routine clinical practice, and its prescription is independent of this study. * Aged 6 to less than 18 years at the time they are prescribed Cosentyx®. * Have valid PASI and IGA mod 2011 score at the time they are prescribed Cosentyx®. Exclusion Criteria: Patients meeting any of the following criteria are not eligible for inclusion in this study: * Patients previously treated with other biologics. * Patients participating in other clinical trials or who previously participated in clinical trials within 30 days before Cosentyx® initiation or a period of 5 half-lives of the investigational drug, whichever is longer. * Patients in conditions which in the judgment of the clinical investigator renders the patient unsuitable for the study.